Bortezomoib-inner-carton (Bortezomoib Inner Carton)
Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 31722-303
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 31722-303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Bortezomoib-outer-carton (Bortezomoib Outer Carton)
Bortezomoib-reconstitution-label (Bortezomoib Reconstitution Label)
This text is a label for Bortezomib for injection, providing instructions for subcutaneous administration along with information on concentration and dilution. The label also mentions to refer to the package insert for full instructions.*
Bortezomoib-vial-label (Bortezomoib Vial Label)
This text provides important details about the medication Bortezomib. It mentions that it is for intravenous or subcutaneous use and comes in a single-dose vial. Each vial contains 3.5 mg of bortezomib and 35 mg of mannitol. The usual dose information should be checked in the accompanying package insert. It further includes storage instructions (20° to 25°C) and a warning that it is a cytotoxic agent. The contact number for the U.S. is provided along with manufacturing information for Camber Pharmaceuticals and Hetero Labs Limited in India.*
Figure1 (Figure1)
Figure2 (Figure2)
The text shows a table displaying the number of patients at risk over time (in months) for two groups ('VoMP(n)' and 'MP(n') along with a reference to a log-rank test and a p-value. These data may be related to a medical study, clinical trial, or survival analysis where the impact of a certain variable or treatment on patient outcomes is being evaluated.*
Figure3 (Figure3)
Figure4 (Figure4)
This is a statistical analysis comparing the effectiveness of Bortezomib and Dexamethasone treatment over time. The data includes the number of patients remaining at different timepoints after receiving each treatment. The p-value from a log-rank test is also provided to evaluate the significance of the differences between the two treatments.*
Figure5 (Figure5)
Figure6 (Figure6)
This text provides information on Hazard Ratio (95% Cl) for two different treatments, VCR-CAP and R-CHOP, over various time points from randomization (in months). The hazard ratio for VCR-CAP is 0.66 with a confidence interval of 0.51 to 0.85. The number of patients receiving each treatment is also listed for each time point. Unfortunately, there is missing information for the VCR-CAP treatment at some time points.*
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
